



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 31/70, 31/715		A2	(11) International Publication Number: WO 93/01820
			(43) International Publication Date: 4 February 1993 (04.02.93)
(21) International Application Number: PCT/US92/05985 (22) International Filing Date: 16 July 1992 (16.07.92) (30) Priority data: 731,214 16 July 1991 (16.07.91) US (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/ US]; 345 Park Avenue, New York, NY 10154 (US). (72) Inventor: CURTIS, Benson, M. ; 1520 N.W. Woodbine Way, Seattle, WA 98177 (US). (74) Agents: POOR, Brian, W.; Bristol-Myers Squibb Com- pany, 3005 First Avenue, Seattle, WA 98121 (US) et al.		(81) Designated States: AU, CA, FI, JP, KR, NO, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE). Published <i>Without international search report and to be republished</i> <i>upon receipt of that report.</i>	
(54) Title: INHIBITION OF NON-CD4 MEDIATED HIV INFECTION			
(57) Abstract <p>A specific nonCD4-gp120 receptor has been isolated which has specific binding affinity for the gp120 surface protein of human immunodeficiency virus (HIV). Methods of treating HIV infection of CD4 negative cells, such as colon and brain, are disclosed together with methods of detecting HIV and diagnostic kits.</p>			

BEST AVAILABLE COPY

THIS PAGE BLANK (USPTO)

INHIBITION OF NON-CD4 MEDIATED HIV INFECTION

TECHNICAL FIELD OF THE INVENTION

5

The present invention is directed to a non-CD4 cell surface receptor for gp120. This gp120 receptor (gp120r) has been isolated and cloned and is utilized in the present invention in methods and kits for the inhibition and detection of HIV infection.

10

BACKGROUND OF THE INVENTION

Two types of human retroviruses have been identified, leukemia viruses and AIDS-related viruses. The primary targets of the human retroviruses are T lymphocytes and cells of the central nervous system. All human retroviruses are transmitted by intimate contact, blood contamination, and infection in utero or after birth by milk. It is likely that all human retroviruses originated in Africa and that they encountered the human species via interspecies infection, possibly from African green monkeys or a related species. The human retroviruses first discovered, Human T Lymphotropic Virus Type 1 (HTLV-1) and Human T Lymphotropic Virus Type II (HTLV-II), have a preferential tropism for T4 cells and some T8 cells, share significant sequence homology, and are mainly associated with T cell leukemias and lymphomas. The other group of human retroviruses, generally called Human Immunodeficiency Viruses (HIV), is discussed in greater detail below. There are two major differences between the two types of human retroviruses: (1) there is substantial genomic variability among various HIV isolates, whereas the genomes of HTLV-I and HTLV-II are stable; and (2) HIV entered human populations much more recently than HTLV-I or HTLV-II.

The human immunodeficiency virus (HIV) is a cytopathic retrovirus and the causative agent of the acquired immunodeficiency syndrome (AIDS). Two forms of HIV have now been identified. The prototype virus, HIV-1, previously termed lymphadenopathy-associated virus (LAV) and Human T Lymphotropic Virus Type III (HTLV-III), is responsible for the vast majority of reported AIDS cases worldwide. Another retrovirus, HIV-2, has been isolated primarily from West African patients with AIDS and is pathogenically related to HIV-1. On the genetic level, HIV-2 is actually more closely related to the simian immunodeficiency virus (SIV), a retrovirus infecting monkeys.

Over half of the people that have contracted AIDS in the United States have already died. As many as three million persons in this country may be asymptomatic carriers of

HIV and are capable of transmitting the virus. It had been estimated in 1986 that 270,000 cases of AIDS will have occurred in the United States by 1991 (U.S. Public Health Service, (1986), Public Health Rep. 101:341). The mortality rate from AIDS is disturbingly high, exceeding 80% within three years of diagnosis and possibly reaching 100% over a longer period.

Worldwide, the AIDS epidemic may involve some five to ten million presently infected persons. Particularly troublesome are statistics from the African continent where millions of individuals are believed infected with HIV, deaths range in the hundreds of thousands, and heterosexual transmission predominates. To date, there is neither a known cure for AIDS nor an effective vaccine against HIV infection.

HIV is a member of the nontransforming, cytopathic lentivirus family of retroviruses. HIV causes a typically fatal disease characterized by severe immunodeficiency or neurodegenerative disease, or both. The primary basis for HIV induced immunosuppression is the depletion of the helper/inducer subset of T lymphocytes expressing the CD4 molecule (T4 or CD4⁺ cells), which serves as a high affinity cell surface receptor for the virus. T4 lymphocytes are involved directly or indirectly in the induction of nearly every immunologic function in the body, and their depletion results in susceptibility to a wide range of opportunistic infections and neoplasms.

In addition to the T4 lymphocyte, other cells expressing the CD4 molecule are targets of HIV infection, especially monocyte-macrophages. HIV infection also results in serious B cell abnormalities including polyclonal activation, hypergammaglobulinemia, elevated levels of circulating immune complexes, and autoantibodies. A decreased number of functional natural killer (NK) cells have also been observed in AIDS patients.

Infection of CD4⁺ cells is initiated by the interaction of the CD4 molecule with the major HIV envelope glycoprotein gp120, an event which is followed by internalization and uncoating of the virion, transcription of genomic RNA to DNA by virus-encoded reverse transcriptase, and integration of the resulting proviral DNA into host cell chromosomal DNA. Also, unintegrated proviral DNA accumulates in large amounts within infected cells and is probably a significant factor in HIV cytopathology (Shaw et al., (1984) Science 226:1165).

The depletion of CD4⁺ T cells appears to contribute significantly to the immunosuppression associated with AIDS. A primary cytopathic effect of the virus in vitro is HIV-induced syncytium formation. CD4, through its interaction with gp120 plays an important role in syncytium formation. However, it has been observed that molecules on the cell surface of uninfected cells other than CD4 are also involved in HIV-induced cell fusion (Hildreth et al. (1989) Science 244:1075-1078).

-3-

Infection by HIV produces, in addition to AIDS, a set of neuropsychiatric disorders which are called the AIDS dementia complex (ADC) (Price et al., (1988) 239:586-592).

The symptoms of ADC include cognitive impairment, apathy and motor dysfunctions, and may affect as many as 90% of AIDS victims. The underlying cause of ADC appears to be the death of brain cells and HIV-1 can be isolated from the brains of infected individuals (Ho et al, (1987) N. Eng. J. Med. 317:278-286).

An early study suggested that the cellular attachment site for HIV in brain might be CD4 (Pert et al., (1986) Proc. Natl. Acad. Sci. USA 83:9254-9258) but attempts to replicate these findings were not successful (Kozlowski et al., (1989) Neurosci. Abstr. 15:671). It now appears unlikely that the CD4 antigen is involved in the infection of brain-derived cells by HIV. Susceptibility of brain cells to infection with HIV-1 does not correlate with the level of expression of CD4 (Chang-Mayer et al., (1987) Proc. Natl. Acad. Sci. USA 84:3526-3530; Srinivasan et al., (1988) Arch. Virol. 98:135-141), and infection of brain-derived cells by HIV-1 is not blocked by anti-CD4 antibodies (Clapham et al., (1989) Nature 337:368-370; Li et al., (1990) J. Virol. 64:1383-1387).

The present invention demonstrates the presence of a non-CD4 receptor for gp120 and a method for the inhibition of HIV infection of cells such as brain and muscle which do not express high levels of CD4.

SUMMARY OF THE INVENTION

Many cells that are susceptible to HIV infection appear to bind gp120 through a non-CD4 surface protein. The present invention has identified this non-CD4 gp120 receptor (gp120r) and has recombinantly expressed and characterized gp120r.

In this invention a specific non-CD4 gp120r has been isolated which has specific binding activity for gp120 present on Human Immunodeficiency Virus-1 (HIV). This gp120r has a molecular weight of about 45, 000 daltons, contains about 400 amino acid residues and is characterized by a Kd for gp120 of about 1.3 nM to about 2.0 nM. The binding of gp120 to gp120r is inhibited by specific carbohydrates, such as mannose and fucose, plant lectins such as concanavalin A and specific antibiotics, such as pradimicin A.

In one embodiment of the present invention, a cDNA molecule that transcribes an mRNA encoding for gp120r is cloned and expressed to produce gp120r. The DNA is selected from a gene library obtained from tissue such as placenta, brain, muscle and colon.

A method of inhibiting HIV infection of mammalian cells, such as brain, muscle and neural cells, is contemplated by the present invention. In this method, cells are contacted with an effective amount of an appropriate inhibitor of gp120r binding for a time

period sufficient to significantly inhibit the binding of HIV to the non-CD4 protein, gp120r. Specific inhibitors of gp120r binding include mannose carbohydrates, fucose carbohydrates, plant lectins, and antibiotics such as pradimicin A.

The gp120r of the present invention can also be utilized in a method and a kit for the detection of the presence of HIV in a fluid sample. In this method, the binding of HIV to gp120r is detected by an indicating means such as a labelled antibody capable of binding to the HIV-gp120r reaction product. It is also contemplated that the gp120r can be affixed to a solid matrix to form a solid support that is useful in this method and/or kit.

DESCRIPTION OF THE FIGURES

In the drawings:

FIGURE 1 illustrates expression cloning of the gp120r cDNA and comparison to CD4.

- A:** Autoradiography of gp120 binding to gp120r and CD4 expressed in COS cells. A-F [¹²⁵I]vgp120; A, gp120r; B, gp120r with G17-2; C, gp120r with 200 nM unlabelled bgp120; D, CD4; E, CD4 with G17-2; F, CD4 with bgp120. G-L [¹²⁵I]ngp120; G, gp102r; H, gp120r with 110.1; I, gp120r with bgp120; J, CD4; K, CD4 with 110.1; L, CD4 with bgp120.
- B:** Inhibition of [¹²⁵I]vgp120 binding to gp120r and CD4. A-F gp120r and G-L CD4. A+G, HIV antisera (1:20; Trimar); B+H, D-galactose (100 mM); C+I, D-mannose (100 mM); D+J, L-fucose (100 mM); E+K, Concanavalin A (1 mg/ml); F+L, pradimicin A (100 µg/ml).
- C:** gp120r binding of HIV. A, HIV; B, HIV with 200 nM bgp120.

FIGURE 2 illustrates the characterization of the gp120r.

- A:** Scatchard analysis of [¹²⁵I]gp120 binding. ▲ - ▲, vgp120 binding to placenta, K_d 1.3 nM, B_{max} 19 fmol/mg protein; ■ with µg/ml G17-2; ● - ●, vgp120 binding to gp120r COS cells, K_d 1.7 nM, B_{max} 150,000 receptors/cell (R/C); ○, ngp120, K_d 1.8 nM, 149,000 R/C.
- B:** Inhibition of [¹²⁵I]gp120 binding to gp120r COS cells. Open symbols ngp120, filled symbols vgp120. The relative values were the same with both forms of gp120. Mannan expressed as mg/ml. □, mannan (IC₅₀ 6 µg/ml); ●, L-fucose (K_i 6 mM); Δ, α-methyl D-mannoside (K_i 15 mM), ○, D-mannose (K_i 23 mM); ◇, N-acetylglucosamine (K_i 70 mM), ■, EGTA (K_i 0.3 mM).

-5-

- 5 C: Internalization of gp120 by gp120r COS cells. Points represent the mean of two experiments with vgp120 and ngp120. ● - ●, surface; ○ - ○ internal.
- D: Placenta control sera; 2, placenta HIV sera; 3, gp120r COS control sera; 4, gp120r COS HIV sera.
- 10 E: Northern blot of gp120r expression. Polyadenylated (A⁺); 2, placenta; 3, thymus; 4+12, forebrain; 5, skeletal muscle; 6, heart; 7, liver; 8, kidney; 9, colon; 10 medulla; 11, cerebellum; 13, T cell (CEM; 16 μg A⁺) 14, B cell (TS-1; 16 μg A⁺); 15, macrophage (U937; 8 μg A⁺); 16, cervical carcinoma (HeLa; 16 μg A⁺). The different apparent size of the ~5 kb band is an artifact of displacement by 28S rRNA.

FIGURE 3 illustrates the sequence analysis of the gp120r.

- 15 A: Nucleotide and deduced protein sequence of gp120r cDNA.
- B: Hydropathicity plot of the gp120r. The predicted transmembrane segment and the start of the eight amphipathic repeats are indicated by arrows.
- C: Aminoacid alignment of the gp120r C-type lectin domain.

DESCRIPTION OF PREFERRED EMBODIMENTS

20 HIV infection of brain and muscle cell lines is not blocked by soluble CD4 or anti-CD4 antibodies (Clapham, P.R. et al., (1989) Nature 337:368-370; Harouse, J.M. et al., (1989) J. Virol. 63:2527-2533; Weber, J. et al., (1989) J. Gen. Virol. 70:2653-2660). This is consistent with the existence of a second gp120 receptor. Binding studies indicated that human placenta was another source for a non-CD4 gp120 receptor, and a cDNA for a

25 second gp120 receptor (gp120r) was isolated by the present invention from a placental library. The gp120r has a higher binding affinity for gp120 than CD4. Sequence analysis revealed homology to membrane associated C-type lectins, and inhibition studies have shown that the receptor binds gp120 through a mannose or fucose containing carbohydrate. The gp120r rapidly internalizes gp120, and is expressed in placenta, thymus, muscle, and

30 colon. These results, when considered with previous studies on the role of gp120 carbohydrate in HIV infection (Lifson, J. et al., (1986) J. Exp. Med. 164:2101-2106; Ezekowitz, R.A.B. et al., (1989) J. Exp. Med. 169:185-196; Larkin M. et al., (1989) AIDS 3: 793-798; Tanabe-Tochikura A. et al., (1990) Virology 176:473-476), suggest a potential role for the gp120r in HIV infection or pathology.

35 The present invention demonstrates that the gp120r participates in cellular binding of HIV by a non-CD4 pathway in muscle and brain, as well as, facilitating virus attachment in CD4 positive cell types. It is likely that the gp120r plays a significant role in

transplacental transport of HIV (Zacher, V. et al., (1991) J. Virol. 65:2102-2107) and colon infection (Barnett, S.W. et al. (1991) Virol. 182:802-809). Gp120 produces an increase in intracellular calcium in rat retinal ganglion cells (Dreyer, E.B. et al., (1990) Science 248:364-367) suggesting that the gp120r or a homologous protein may have signaling functions in the nervous system disrupted by gp120 leading to HIV neurotoxicity.

5 In the present invention, a new non-CD4 binding protein, or receptor, for gp120 was isolated. The HIV surface protein gp120 was found to bind to a receptor on human placental membranes that was not blocked by antibodies directed against CD4, such as G17-2 and OKT4a, and which interfere with gp120 binding to CD4. A cDNA encoding this receptor was isolated from a placental cDNA library in a mammalian expression vector (pCDM8). The gene products were expressed in COS cells and were screened by ¹²⁵I-
10 labelled gp120 binding. From a pool of 90,000 cDNA molecules, a single clone was isolated that encoded a protein which bound gp120, even in the presence of concentrations of anti-CD4 antibody (G17-2) which completely blocked gp120 binding to CD4.

15 Sequence studies were carried out and indicated that the 1.5 kilobase cDNA clone encoded a previously unknown member of a family of Type II membrane proteins with an extracellular C type lectin domain.

The cloned gp120r of the present invention binds gp120 with an affinity (Kd) of about 1 to 2 nM, which is considerably greater than the affinity of CD4 for gp120 (about
20 Kd = 4 nM).

The binding of gp120 to gp120r is not blocked by polyclonal HIV antisera, but is inhibited by mannose carbohydrates, fucose carbohydrates, plant lectins such as concanavalin A and pradimicin A antibiotics. Other sugars such as N-acetyl-d-glucosamine and galactose are less potent inhibitors.

25 The gp120r is expressed on many mammalian cells which do not exhibit high levels of CD4, such as placenta, skeletal muscle, brain, and mucosal cells. Other tissue and cells displaying gp120r include colon, thymus, heart, T cells, B cells and macrophages. The distribution of tissue having gp120r parallels that for binding of gp120 which is not blocked by CD4 antibodies, and for HIV infection which is not neutralized by soluble
30 CD4. This observation suggests a role for gp120r in viral infection.

In gp120r expressing transfected COS cells, gp120 is rapidly internalized following binding to gp120r. This binding and internalization of gp120 is inhibited by compounds such as mannan, concanavalin A and pradimicin A.

35 In the present invention a cDNA which encodes gp120 was isolated and cloned. A DNA molecule of the present invention corresponds to a complementary DNA molecule which transcribes a messenger RNA (mRNA) molecule which, when translated, encodes gp120r. The cDNA molecules were obtained by reverse-transcribing mRNA molecules

isolated from mammalian tissue such as placenta, colon, brain or thymus. The transcription and cloning of cDNA molecules and isolation of gene products are techniques well known in the art and, for example, are described in Sambrook et al., "Molecular Cloning: A Laboratory Manual", 2d edition, Cold Spring Harbor Lab., Cold Spring Harbor, NY (1989), which is incorporated herein by reference.

As used herein, the phrases "physiologically tolerable" and "pharmaceutically acceptable" refer to molecular entities and compositions that do not produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a mammal. The physiologically tolerable carrier may take a wide variety of forms depending upon the preparation desired for administration and the intended route of administration.

A carrier is a material useful for administering the active compound and must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof.

The pharmaceutical compositions are prepared by any of the methods well known in the art of pharmacy all of which involve bringing into association the active compound and the carrier therefor.

For therapeutic use, the agent utilized in the present invention can be administered in the form of conventional pharmaceutical compositions. Such compositions can be formulated so as to be suitable for oral or parenteral administration, or as suppositories. In these compositions, the agent is typically dissolved or dispersed in a physiologically tolerable carrier.

As an example, the compounds of the present invention can be utilized in liquid compositions such as sterile suspensions or solutions, or as isotonic preparations containing suitable preservatives. Particularly well suited for the present purposes are injectable media constituted by aqueous injectable isotonic and sterile saline or glucose solutions. Additional liquid forms in which the present compounds may be incorporated for administration include flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, peanut oil, and the like, as well as elixirs and similar pharmaceutical vehicles.

The present agents can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to the agent of the present invention, stabilizers,

preservatives, expedients, and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic.

Methods to form liposomes are known in the art. See, for example, Prescott, Ed., "Methods in Cell Biology", Volume XIV, Academic Press, New York, N.Y. (1976) p 33 et seq.

5 The present compounds can also be used in compositions such as tablets or pills, preferably containing a unit dose of the compound. To this end, the agent (active ingredient) is mixed with conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, gums or
10 similar materials as non-toxic, physiologically tolerable carriers. The tablets or pills of the present compositions can be laminated or otherwise compounded to provide unit dosage forms affording prolonged or delayed action.

It should be understood that in addition to the aforementioned carrier ingredients the pharmaceutical formulation described herein can include, as appropriate, one or more
15 additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface active agents, thickeners, lubricants, preservatives (including antioxidants) and the like, and substances included for the purpose of rendering the formulation isotonic with the blood of the intended recipient.

The tablets or pills can also be provided with an enteric layer in the form of an
20 envelope that serves to resist disintegration in the stomach and permits the active ingredient to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, including polymeric acids or mixtures of such acids with such materials as shellac, shellac and cetyl alcohol, cellulose acetate, and the like. A particularly suitable enteric coating comprises a styrene-maleic
25 acid copolymer together with known materials that contribute to the enteric properties of the coating.

A method of inhibiting HIV infection of mammalian cells is disclosed in the present invention. A pharmaceutical composition containing a compound which effectively inhibits the binding of gp120r to HIV, is contacted with cells either in vitro or in vivo for a time
30 period sufficient to significantly inhibit the binding of HIV to the cell surface.

Compounds effective in this method include mannose carbohydrates, fucose carbohydrates, plant lectins and pradimicin A antibiotics. Specifically preferred compounds are mannose, fucose, mannan, concanavalin A and pradimicin A. The pharmaceutical composition of the present invention includes a compound which effectively
35 inhibits gp120r binding to HIV and may also include a physiologically tolerable carrier.

The method of the present invention is preferably utilized to inhibit HIV infection of placental, brain, muscle, neural and colon cells.

A diagnostic method is also described in the present invention for detecting the presence, and preferably the amount, of HIV present in a fluid sample by producing a reaction product containing HIV bound to gp120r. Those skilled in the art will recognize that there are well known clinical diagnostic procedures that can be utilized for the formulation and detection of such reaction products. Thus, while exemplary assay methods are described herein, the invention is not intended to be so limited.

Various heterogeneous and homogeneous assay protocols can be employed for detecting the presence, and preferably the amount, of HIV in a fluid sample. For example, the present invention contemplates a method for assaying a sample, such as a body fluid, for the presence of HIV comprising the steps of:

- (a) admixing a fluid sample with gp120r, either in solution or affixed to a solid matrix;
- (b) maintaining the admixture for a predetermined time period such as about 10 minutes to about 16 - 20 hours and under biological assay conditions at a temperature of about 4°C to about 45°C that is sufficient for any HIV present in the sample to react with (bind) the gp120r to form a reaction product; and
- (c) determining the presence of any reaction product that is formed, and thereby the presence of any HIV in the admixture.

Preferably, the fluid sample is a body fluid sample, such as blood, plasma, serum, urine, saliva, semen or cerebrospinal fluid (CSF).

The determination of the presence of a reaction product, either directly or indirectly, can be accomplished by assay techniques well known in the art such as by the use of an indicating or labelling means, as discussed hereinbelow. In a preferred embodiment, a labelled indicating means, such as a fluorescein-labelled antibody, is capable of binding to the gp120r present in the reaction product to form a labelled complex. Determining the presence of the labelled complex provides an assay for the presence of HIV in the sample. In particularly preferred embodiments, the amount of labelled indicating means bound as part of the complex is determined, and thereby the amount of HIV present in the sample is determined. When that amount is zero, no HIV is present in the sample, within the limits of detection. Methods for assaying the presence and amount of a labelled indicating means depend on the label used, such labels and assay methods being well known in the art.

In a preferred embodiment, the gp120r is affixed on a solid matrix to form a solid phase support. In that embodiment, the assay is heterogeneous, solid/liquid phase assay and, as such, has its own preferred manipulations. For example, following admixing of a liquid sample with a solid support containing gp120r affixed thereto, the admixture is

maintained under biological assay conditions for a time period sufficient for any HIV present in the sample to bind to gp120r and form a solid phase bound reaction product. The solid and liquid phases are then separated to remove any material in the sample that did not react with the solid support, such as by rinsing. This removes any material present in the sample that could interfere with the detection of the reaction product.

5 A labelled indicating means is then admixed with the separated solid phase in an aqueous medium to form a solid/liquid phase labelling-reaction admixture which is maintained for a time period sufficient for the indicating means to bind to the solid bound reaction product forming a labelled complex. The solid phase is then separated from the liquid phase, rinsed and the presence, and preferably amount, of the indicating means present is determined.

As used herein, the term "biological assay conditions" refers to parameters that maintain the biological activity of the molecules and organisms in the present invention, and include a temperature range of about 4°C to about 45°C, a pH value range of about 5 to about 9, and an ionic strength varying from that of distilled water to that of about one molar sodium chloride. Methods for optimizing such conditions are well known in the art.

As used herein, the term "about" refers to a range of values both greater than and/or less than the listed value by 10% or less. For example, a temperature of about 20° C will include temperature values of from 18° C to 22° C.

As used herein, the term "corresponds", and its various grammatical modifications, means "is similar or in agreement with".

A diagnostic system in kit form for assaying a fluid sample for the presence of HIV is also contemplated by the present invention. Such a kit includes, in an amount sufficient for at least one assay, gp120r as a packaged reagent, together with instructions for use. An indicating means capable of detecting or signalling the presence of a reaction product formed between gp120r and HIV may also be present in the kit as a separately packaged reagent.

As used herein, the term "instructions for use" typically includes a tangible expression describing the reagent concentration or at least one assay method parameter such as the relative amounts of reagent and sample to be admixed, maintenance time periods for admixtures, temperature, buffer conditions and the like.

The packaging materials discussed herein in relation to diagnostic systems are those customarily utilized. Such materials include glass and plastic (e.g. polyethylene, polypropylene and polycarbonate) bottles, vials, plastic and plastic-foil laminated envelopes and the like.

As used herein, the term "package" refers to a solid material such as glass, plastic, paper, foil and the like capable of holding within fixed limits the gp120r, and preferably

also a detection means. In one embodiment, the package can contain a microtiter plate well to which microgram quantities of gp120r have been operatively affixed, ie., linked so as to be capable of reacting with and bind HIV and/or gp120.

As used herein, the terms "label" "indicating means" and "labelled indicating means", in their various grammatical forms refer to single atoms and molecules that are either directly or indirectly involved in the production of a detectable signal to indicate or detect the presence of a reaction product. Such labels are themselves well known in clinical diagnostic chemistry and constitute a part of this invention only insofar as they are utilized with otherwise novel methods and/or systems.

The indicating means can be a fluorescent labelling agent that chemically binds to antibodies or protein antigens without denaturing them to form a fluorochrome (dye) that is a useful immunofluorescent tracer. Suitable fluorescent labelling agents are fluorochrome, such as fluorescein isocyanate (FIC), fluorescein isothiocyanate (FITC), 5-dimethylamine-1-naphthalene sulfonyl chloride (DANSC), tetramethylrhodamine isocyanate (TRITC), lissamine and the like. Immunofluorescence analysis techniques are well known in the art, and for example, is described in DeLuca, "Immunofluorescence Analysis" in Immunofluorescence Analysis, Marchalonis et al., (1982) eds., John Wiley & Sons, Ltd., pp. 189-231, which is incorporated herein by reference.

Other preferred indicating means are colorimetric agents and enzymes, such as horseradish peroxidase, glucose oxidase or the like, linked as described above, as well as radioactive elements, preferably an element that produces gamma ray emissions. Elements which emit gamma rays, such as ^{124}I , ^{125}I , ^{128}I , ^{132}I , and ^{51}Cr represent one class of radioactive indicating groups. Another group of useful labelling means are those elements such as ^{11}C , ^{18}F , ^{15}O and ^{13}N which emit positrons. The positrons so emitted produce gamma rays upon interaction with electrons present.

Having generally described this invention, a further understanding can be obtained by reference to certain specific examples which are provided herein for purposes of illustration only and are not intended to be limiting unless otherwise specified.

EXAMPLE 1

Cloning and Isolation of Non-CD4 Gp140 Receptor Protein

Human placental membranes were found to be able to bind vaccinia derived recombinant gp120 (vgp120) with a K_d of 1.3 nM. At nM (concentrations) of gp120 none of this binding was inhibited by an antibody (G17-2) which has been reported to efficiently block gp120 binding to CD4 (Linsley et al. (1988) J. Virol. 62:3695-3702), as shown in

FIGURE 2A. Approximately 50 - 90% of the total placental gp120 binding was not due to CD4.

A placental cDNA library was obtained in the mammalian expression vector pCDM8 and was screened. A cDNA was isolated which expressed protein that exhibited high affinity binding for vgp120 in the presence of G17-2.

This protein, designated as gp120 receptor (gp120r), also bound native gp120 (ngp120), and the binding component was precipitated in the presence of an antibody directed against gp120.

EXAMPLE 2

Characterization

The binding of radiolabelled gp120 to gp120r expressed in COS-7 cells was studied. Pools of 90,000 cDNA molecules, obtained from a placental pCDM8 library, were transfected by electroporation into COS-7 cells. Cells which expressed gp120r on the surface was identified by screening with either 1 nM of ^{125}I -labelled vgp120 (^{125}I -vgp120) or ^{125}I -ngp120 by the method described in Kozlowski et al., (1990) Antivir. Chem. Chemother. 1:175-182, incorporated herein by reference. The results of binding studies utilizing the transfected COS-7 cells are shown in FIGURE 1.

Binding of labelled gp120 (1 nM) to the cells was carried out following a 1 hour preincubation of the cells or GP120 at 22°C with one or more of the following: anti-CD4 antibody G17-2 (5 ug/ml), baculovirus-derived gp120 (bgp120, American Biotechnologies, 200 nM), anti-gp120 monoclonal antibody 110.1 (25 ug/ml), D-mannose (100 mM), D-galactose (100 mM), L-fucose (100 mM), concanavalin A (1 mg/ml) or pradiimicin A (100 ug/ml). The cells were monitored after autoradiography (3 days). The results seen in FIGURES 1 (A and B) illustrate that gp120 binding to the gp120r expressed on the cells was blocked by excess bgp120, mannose, fucose, pradiimicin A, Concanavalin A, and preincubation with antibody 110.1 but not by CD4, antibody G17-2, galactose, or HIV antisera. Studies were also carried out on gp120 binding to CD4 expressing COS cells, transfected with π H3MCD4 by the method of Peterson et al. (1988) Cell 54:65-72.

Control studies of the binding of ^{125}I -labelled psoralen-UV inactivated HIV-BRU to the gp120r expressing COS-7 cells demonstrated binding of HIV to gp120r and blockage by excess bgp120 (FIGURE 1C). A tabular compilation quantitating the amount of bound material to the cells in FIGURE 1 is shown in Table. 1

TABLE 1

FIGURE 1	LABELLED MATERIAL	COMPETITION WITH	CPM BOUND X 10 ⁻³	
			GP120R	CD4
A	vgp120+	—	60	20
		G17-2	60	5
		bgp120	6	4
B	vgp120+	HIV antisera	63	3
		D-galactose	50	20
		D-mannose	6	20
		L-fucose	6	20
		concanavalin A	8	6
		pradimicin A	8	6
		OKT4A	60	5
		N-acetylgalactosamine	60	20
		N-acetylglucosamine	30	20
		mannan	6	20
		mannose-6-phosphate	60	20
		sialic acid	60	20
		human IgE	60	20
C	HIV-BRU+	—	8	4
		bgp120	2	2

Scatchard plots of gp120 binding to placental membranes and to COS cells expressing the gp120r were carried out in the presence and absence of a 200 fold excess of bgp120 or ngp120. The results, shown in FIGURE 2A, demonstrate a specific binding of vgp120 to gp120r with a K_d of 1.7 nM ± 0.4 (n=4) and of ngp120 to gp120r with K_d of 1.8 nM ± 0.2 (n=4), with 150,000 and 149,000 receptors per cell, respectively. Concurrent analysis of gp120 binding to CD4 expressed on COS cells gave a K_d of 4-5 nM in agreement with previous reports (Linsley, P.S. et al. (1988) J. Virol 62:3695-3702; Schnittman, et al. (1988) J. Immunol. 141:4181-4186). Calculations from the association and dissociation rate constants gave a similar comparative result. The expressed gp120r has a relative molecular mass (Mr) of ~48,500 and a protein of similar size was also partially purified from placental membranes (FIGURE 2D).

The placental membranes and COS cells were surface iodinated, and treated with 1 nM unlabelled vgp120, then washed with Blotto RPMI, 5% BSA, 1% Non-fat dry milk, 0.2% sodium azide solubilized in Triton X-100 (1% in PBS with a protein inhibitor cocktail, PMSF, Pepstatin A, orthophenathroline and leupeptin) and immunoprecipitated

with HIV or control human sera, according to the method described in Curtis et al. (1990) J. Immunol. 144:1295-1303.

5 Northern analysis of the expression of the gp120r RNA indicated a major species of ~5 kb and a minor species of ~1.7 kb which may represent an alternatively processed transcript and is more consistent with the size of the gp120r cDNA. RNA was denatured, separated in an agarose gel, transferred to nitrocellulose, hybridized to gp120r cDNA and autoradiographed for 3 days.

10 Expression of gp120r RNA was highest in colon followed by thymus, placenta, heart, skeletal muscle, and was not detected in liver or kidney. Low levels of expression in brain, T cell, B cell, and macrophage (FIGURE 2E) require verification by polymerase chain reaction (PCR). Full length CD4 RNA was highest in thymus, T cell, and macrophage followed by placenta and colon (not shown).

The gp120r cDNA encodes a protein of 404 amino acids with a calculated Mr of 45,775 (FIGURE 3A).

15 Sequencing of both strands of gp120r cDNA was carried out by the dideoxy chain termination method. The nucleotide sequence preceeding the first ATG agrees with the Kozak consensus. The predicted cytoplasmic domain has a similar length and shows some sequence homology to other type II membrane protein C-type lectins (Spiess, M. (1990) Biochemistry 29:10009-10018). The membrane spanning sequence is underlined and was
20 predicted in part by homology to related sequences in FIGURE 3C. The potential N-linked glycosylation site is marked by an asterisk. The start of the seven complete and eighth partial tandem repeats are indicated (R1-R8). The consensus repeat sequence is IYQELT(R/Q) LKAAVGELPEKSKLQE. The beginning of the lectin domains is also indicated (L). No signal sequence was apparent but instead demonstrated homology to a
25 family of Type II membrane proteins which utilize a ~20 residue hydrophobic stop-transfer sequence for membrane translocation. The "positive inside rule" (von Heijne, G. et al. (1988) Eur. J. Biochem. 174:671-678) for the sequence within fifteen residues of the transmembrane region predicts a cytoplasmic amino terminus in agreement with the homology to membrane associated C-type lectins with similar membrane orientation
30 (FIGURE 3C) (Spiess, M. (1990) Biochemistry 29:10009-10018). This region, Met 1 to Ala 76, represents the first domain of the gp120r sequence.

The second domain (Ile 77 to Val 249) consists of tandem repeats of nearly identical sequence (FIGURE 3A). This region was predicted to consist of a series of amphipathic α -helices interrupted by β -turns. Circular Dichroism spectra in 40% trifluoroethanol of a consensus repeat peptide beginning with the β -turn,
35 PEKSKLQEIIYQELTQLKAAVGEL (single-letter amino-acid code), demonstrated an all α -helical structure (not shown). Homology to other repeat domains suggested three possible

tertiary structures, (1) antiparallel helix bundles, (2) a multimeric parallel helix bundle, and (3) a membrane pore with a hydrophobic exterior and a negatively charged interior. The first two models would function as spacers to separate the lectin domain from the membrane, while the third could generate a transmembrane signal after ligand binding.

5 The third domain (Cys 253 to Ala 404) is homologous to the other known C-type lectins which are type II membrane proteins (FIGURE 3C). With the exception of the IgEr, these lectins bind terminal D-galactose and D-N-acetylgalactosamine of glycoproteins (Spiess, M. (1990) *Biochemistry* **29**: 10009-10018).

10 The most closely related sequences were the group of Type II membrane protein C-type lectins: Chick hepatic lectin (CHL) (Drickamer, K.J. (1981) *Biol. Chem.* **256**:5827-5839), low affinity IgE receptor (IgEr) (Kikutani, H. et al. (1986) *Cell* **47**: 657-665), the asialoglycoptorein receptors (human H1 and H2 (Spiess, M. et al. (1985) *Proc. Natl. Acad. Sci. USA* **82**:6465-6569) are shown), and the rat Kupffer cell receptor (Hoyle, G.W. et al. (1988) *J. Biol. Chem.* **263**:7487-7492). The most similar mannose binding
15 lectin was one of the eight carbohydrate recognition domains of the human macrophage mannose receptor (Mannr) (Taylor, M.E. et al. (1990) *J. Biol. Chem.* **265**:12156-12162; Ezekowitz, R.A.B. et al. (1990) *J. Exp. Med.* **172**:1785-1794). Residues identical to the
20 gp120r are boxed. ALIGN scores indicate significant sequence similarity if greater than 3.0. The complete gp120r sequence was most homologous to the Kupffer cell receptor which has a similar tandem repeat (Hoyle, G.W. et al. (1988) *J. Biol. Chem.* **263**:7487-7492).

 The inability to crosslink gp120 to the non-CD4 sites on placenta and brain cell lines (not shown) was consistent with an interaction of the gp120r with carbohydrate, and polyclonal HIV antisera added to gp120 blocked binding to CD4 but not to the gp120r
25 (FIGURE 1B). Galactose and N-acetylgalactosamine did not block gp120 binding, but mannose and fucose completely blocked binding to the gp120r without an effect on CD4 (FIGURE 1B). Inhibition by a series of sugars is shown in FIGURE 2B. Human IgE (10 μ g/ml), sialic acid (100 mM), and mannose-6-phosphate (100 mM) had no effect on binding to the gp120r. The three forms of gp120 used have different oligosaccharide
30 structures. Bgp120 contains only high mannose structures (Hsieh, P. et al. (1984) *J. Biol. Chem.* **259**:2375-2382). Vgp120 has equal proportions of high mannose and complex (Mizuochi, T. et al. (1988) *Biochem. J.* **254**:599-603) similar to ngp120 which has a greater structural diversity in the complex chains (Geyer, H. et al. (1988) *J. Biol. Chem.* **263**:11760-11767; Mizuochi, T. et al. (1990) *J. Biol. Chem.* **265**:8519-8524). The
35 affinity of the gp120r for all three forms was similar (FIGURE 2A) suggesting that the terminal mannose of high mannose chains are the primary determinants of binding. As expected for a C-type lectin the gp120r required calcium and binding was blocked by

EGTA (FIGURE 2B). The gp120r carbohydrate specificity is more closely related to serum mannose binding proteins and to the Mr 175,000 mannose-specific endocytosis receptor found in macrophages and placenta (Taylor, M.E. et al. (1990) J. Biol. Chem. 265:12156-12162; Ezekowitz, R.A.B. et al. (1990) J. Exp. Med. 172:1785-1794) (FIGURE 3C). Low (1 nM) concentrations of gp120 did not purify a Mr 175,000 band from placental membranes (FIGURE 2D) consistent with a reported concentration of 150-300 nM for gp120 saturation of the macrophage receptor (Larkin, M. et al. (1989) AIDS 3, 793-798).

The importance of gp120 carbohydrate in HIV infection has been suggested by the ability of plant lectins (Lifson, J. et al. (1986) E. J. Exp. Med. 164:2101-2106) and serum mannose-binding protein (Ezekowitz, R.A.B. et al. (1989) J. Exp. Med. 169:185-196) to block infection, and a proposed role for the macrophage endocytosis receptor in viral attachment (Larking M. et al. (1989) AIDS 3, 793-798). Concanavalin A treatment of gp120 blocked binding to the gp120r and CD4 (FIGURE 1B), consistent with a steric hindrance of receptor interaction. The antibiotic pradimicin A blocks HIV infection of CD4 positive T cells and this inhibitory effect is prevented by mannan and EGTA (Tanabe-Tochikura, A. et al. (1990) Virology 176:476-473). Pradamicin blocked gp120 binding to the gp120r and CD4, while mannan and EGTA only inhibited binding to the gp120r (FIGURE 2B). Mannan inhibited ~10% of high affinity (nM) gp120 binding to T cells and macrophages, consistent with gp120r expression (FIGURE 2E), suggesting that in addition to CD4 the gp120r may be important for HIV binding and infection. The observation the the gp120r rapidly internalized its bound ligand gp120 (FIGURE 2C), and also binds radiolabelled HIV in a gp120 dependent fashion (FIGURE 1C) also support this conclusion.

The foregoing description and Examples are intended as illustrative of the present invention, but not as limiting. Numerous variations and modifications may be effected without departing from the true spirit and scope of the present invention.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Curtis, Benson
- (ii) TITLE OF INVENTION: INHIBITION OF NON-CD4 MEDIATED HIV INFECTION
- (iii) NUMBER OF SEQUENCES: 9
- (iv) CORRESPONDENCE ADDRESS:
- (A) ADDRESSEE: Bristol-Myers Squibb Company
(B) STREET: 3005 First Avenue
(C) CITY: Seattle
(D) STATE: Washington
(E) COUNTRY: USA
(F) ZIP: 98121
- (v) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
- (A) APPLICATION NUMBER: US UNKNOWN
(B) FILING DATE: 11-JUL-1991
(C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
- (A) NAME: Sorrentino, Joseph M.
(B) REGISTRATION NUMBER: 32,598
(C) REFERENCE/DOCKET NUMBER: ON0086-
- (ix) TELECOMMUNICATION INFORMATION:
- (A) TELEPHONE: (206) 728-4800
(B) TELEFAX: (206) 448-4775

SUBSTITUTE SHEET

WO 93/01820

- 18 -

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1312 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Human immunodeficiency virus type 1

(ix) FEATURE:

(A) NAME/KEY: CDS
 (B) LOCATION: 42..1253

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

CTAAAGCAGG AGTTCTGGAC ACTGGGGGAG AGTGGGGTGA C ATG AGT GAC TCC 53
 Met Ser Asp Ser
 1

AAG GAA CCA AGA CTG CAG CAG CTG GGC CTC CTG GAG GAG GAA CAG CTG 101
 Lys Glu Pro Arg Leu Gln Gln Leu Gly Leu Leu Glu Glu Glu Gln Leu 20
 5 10 15

AGA GGC CTT GGA TTC CGA CAG ACT CGA GGA TAC AAG AGC TTA GCA GGG 149
 Arg Gly Leu Gly Phe Arg Gln Thr Arg Gly Tyr Lys Ser Leu Ala Gly 35
 25 30

TGT CTT GGC CAT GGT CCC CTG GTG CTG CAA CTC CTC TCC TTC ACG CTC 197
 Cys Leu Gly His Gly Pro Leu Val Leu Gln Leu Leu Ser Phe Thr Leu 50
 40 45

TTG GCT GGG CTC CTT GTC CAA GTG TCC AAG GTC CCC AGC TCC ATA AGT 245
 Leu Ala Gly Leu Leu Val Gln Val Ser Lys Val Pro Ser Ser Ile Ser 65
 55 60

CAG GAA CAA TCC AGG CAA GAC GCG ATC TAC CAG AAC CTG ACC CAG CTT 293
 Gln Glu Gln Ser Arg Gln Asp Ala Ile Tyr Gln Asn Leu Thr Gln Leu 80
 70 75

AAA GCT GCA GTG GGT GAG CTC TCA GAG AAA TCC AAG CTG CAG GAG ATC 341
 Lys Ala Ala Val Gly Glu Leu Ser Glu Lys Ser Lys Leu Gln Glu Ile 100
 85 90 95

SUBSTITUTE SHEET

- 19 -

TAC CAG GAG CTG ACC CAG CTG AAG GCT GCA GTG GGT GAG CTT CCA GAG Tyr Gln Glu Leu Thr Gln Leu Lys Ala Ala Val Gly Glu Leu Pro Glu 105 110 115	389
AAA TCT AAG CTG CAG GAG ATC TAC CAG GAG CTG ACC CGG CTG AAG GCT Lys Ser Lys Leu Gln Glu Ile Tyr Gln Glu Leu Thr Arg Leu Lys Ala 120 125 130	437
GCA GTG GGT GAG CTT CCA GAG AAA TCT AAG CTG CAG GAG ATC TAC CAG Ala Val Gly Glu Leu Pro Glu Lys Ser Lys Leu Gln Glu Ile Tyr Gln 135 140 145	485
GAG CTG ACC TGG CTG AAG GCT GCA GTG GGT GAG CTT CCA GAG AAA TCT Glu Leu Thr Trp Leu Lys Ala Ala Val Gly Glu Leu Pro Glu Lys Ser 150 155 160	533
AAG ATG CAG GAG ATC TAC CAG GAG CTG ACT CGG CTG AAG GCT GCA GTG Lys Met Gln Glu Ile Tyr Gln Glu Leu Thr Arg Leu Lys Ala Ala Val 165 170 175 180	581
GGT GAG CTT CCA GAG AAA TCT AAG CAG CAG GAG ATC TAC CAG GAG CTG Gly Glu Leu Pro Glu Lys Ser Lys Gln Gln Glu Ile Tyr Gln Glu Leu 185 190 195	629
ACC CGG CTG AAG GCT GCA GTG GGT GAG CTT CCA GAG AAA TCT AAG CAG Thr Arg Leu Lys Ala Ala Val Gly Glu Leu Pro Glu Lys Ser Lys Gln 200 205 210	677
CAG GAG ATC TAC CAG GAG CTG ACC CGG CTG AAG GCT GCA GTG GGT GAG Gln Glu Ile Tyr Gln Glu Leu Thr Arg Leu Lys Ala Ala Val Gly Glu 215 220 225	725
CTT CCA GAG AAA TCT AAG CAG CAG GAG ATC TAC CAG GAG CTG ACC CAG Leu Pro Glu Lys Ser Lys Gln Gln Glu Ile Tyr Gln Glu Leu Thr Gln 230 235 240	773
CTG AAG GCT GCA GTG GAA CGC CTG TGC CAC CCC TGT CCC TGG GAA TGG Leu Lys Ala Ala Val Glu Arg Leu Cys His Pro Cys Pro Trp Glu Trp 245 250 255 260	821
ACA TTC TTC CAA GGA AAC TGT TAC TTC ATG TCT AAC TCC CAG CGG AAC Thr Phe Phe Gln Gly Asn Cys Tyr Phe Met Ser Asn Ser Gln Arg Asn 265 270 275	869
TGG CAC GAC TCC ATC ACC GCC TGC AAA GAA GTG GGG GCC CAG CTC GTC Trp His Asp Ser Ile Thr Ala Cys Lys Glu Val Gly Ala Gln Leu Val 280 285 290	917
GTA ATC AAA AGT GCT GAG GAG CAG AAC TTC CTA CAG CTG CAG TCT TCC Val Ile Lys Ser Ala Glu Glu Gln Asn Phe Leu Gln Leu Gln Ser Ser 295 300 305	965

SUBSTITUTE SHEET

WO 93/01820

- 20 -

AGA AGT AAC CGC TTC ACC TGG ATG GGA CTT TCA GAT CTA AAT CAG GAA 1013
 Arg Ser Asn Arg Phe Thr Trp Met Gly Leu Ser Asp Leu Asn Gln Glu
 310 315 320

GGC ACG TGG CAA TGG GTG GAC GGC TCA CCT CTG TTG CCC AGC TTC AAG 1061
 Gly Thr Trp Gln Trp Val Asp Gly Ser Pro Leu Leu Pro Ser Phe Lys
 325 330 335 340

CAG TAT TGG AAC AGA GGA GAG CCC AAC AAC GTT GGG GAG GAA GAC TGC 1109
 Gln Tyr Trp Asn Arg Gly Glu Pro Asn Asn Val Gly Glu Glu Asp Cys
 345 350 355

GCG GAA TTT AGT GGC AAT GGC TGG AAC GAC GAC AAA TGT AAT CTT GCC 1157
 Ala Glu Phe Ser Gly Asn Gly Trp Asn Asp Asp Lys Cys Asn Leu Ala
 360 365 370

AAA TTC TGG ATC TGC AAA AAG TCC GCA GCC TCC TGC TCC AGG GAT GAA 1205
 Lys Phe Trp Ile Cys Lys Lys Ser Ala Ala Ser Cys Ser Arg Asp Glu
 375 380 385

GAA CAG TTT CTT TCT CCA GCC CCT GCC ACC CCA AAC CCC CCT CCT GCG 1253
 Glu Gln Phe Leu Ser Pro Ala Pro Ala Thr Pro Asn Pro Pro Pro Ala
 390 395 400

TAGCAGAACT TCACCCCCTT TTAAGCTACA GTTCCTTCTC TCCATCCTTC GACCTTTAG 1312

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 404 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

*idem DC-SIGN de la fig 9
 de D1 (séquence vérifiée)*

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Ser Asp Ser Lys Glu Pro Arg Leu Gln Gln Leu Gly Leu Leu Glu
 1 5 10 15

Glu Glu Gln Leu Arg Gly Leu Gly Phe Arg Gln Thr Arg Gly Tyr Lys
 20 25 30

Ser Leu Ala Gly Cys Leu Gly His Gly Pro Leu Val Leu Gln Leu Leu
 35 40 45

Ser Phe Thr Leu Leu Ala Gly Leu Leu Val Gln Val Ser Lys Val Pro
 50 55 60

SUBSTITUTE SHEET

- 21 -

Ser Ser Ile Ser Gln Glu Gln Ser Arg Gln Asp Ala Ile Tyr Gln Asn
 65 70 75 80
 Leu Thr Gln Leu Lys Ala Ala Val Gly Glu Leu Ser Glu Lys Ser Lys
 85 90 95
 Leu Gln Glu Ile Tyr Gln Glu Leu Thr Gln Leu Lys Ala Ala Val Gly
 100 105 110
 Glu Leu Pro Glu Lys Ser Lys Leu Gln Glu Ile Tyr Gln Glu Leu Thr
 115 120 125
 Arg Leu Lys Ala Ala Val Gly Glu Leu Pro Glu Lys Ser Lys Leu Gln
 130 135 140
 Glu Ile Tyr Gln Glu Leu Thr Trp Leu Lys Ala Ala Val Gly Glu Leu
 145 150 155 160
 Pro Glu Lys Ser Lys Met Gln Glu Ile Tyr Gln Glu Leu Thr Arg Leu
 165 170 175
 Lys Ala Ala Val Gly Glu Leu Pro Glu Lys Ser Lys Gln Gln Glu Ile
 180 185 190
 Tyr Gln Glu Leu Thr Arg Leu Lys Ala Ala Val Gly Glu Leu Pro Glu
 195 200 205
 Lys Ser Lys Gln Gln Glu Ile Tyr Gln Glu Leu Thr Arg Leu Lys Ala
 210 215 220
 Ala Val Gly Glu Leu Pro Glu Lys Ser Lys Gln Gln Glu Ile Tyr Gln
 225 230 235 240
 Glu Leu Thr Gln Leu Lys Ala Ala Val Glu Arg Leu Cys His Pro Cys
 245 250 255
 Pro Trp Glu Trp Thr Phe Phe Gln Gly Asn Cys Tyr Phe Met Ser Asn
 260 265 270
 Ser Gln Arg Asn Trp His Asp Ser Ile Thr Ala Cys Lys Glu Val Gly
 275 280 285
 Ala Gln Leu Val Val Ile Lys Ser Ala Glu Glu Gln Asn Phe Leu Gln
 290 295 300
 Leu Gln Ser Ser Arg Ser Asn Arg Phe Thr Trp Met Gly Leu Ser Asp
 305 310 315 320
 Leu Asn Gln Glu Gly Thr Trp Gln Trp Val Asp Gly Ser Pro Leu Leu
 325 330 335
 Pro Ser Phe Lys Gln Tyr Trp Asn Arg Gly Glu Pro Asn Asn Val Gly
 340 345 350

SUBSTITUTE SHEET

Glu Glu Asp Cys Ala Glu Phe Ser Gly Asn Gly Trp Asn Asp Asp Lys
 355 360 365
 Cys Asn Leu Ala Lys Phe Trp Ile Cys Lys Lys Ser Ala Ala Ser Cys
 370 375 380
 Ser Arg Asp Glu Glu Gln Phe Leu Ser Pro Ala Pro Ala Thr Pro Asn
 385 390 395 400
 Pro Pro Pro Ala

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 127 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Human immunodeficiency virus type 1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Cys His Pro Cys Pro Trp Glu Trp Thr Phe Phe Gln Gly Asn Cys Tyr
 1 5 10 15
 Phe Met Ser Asn Ser Gln Arg Asn Trp His Asp Ser Ile Thr Ala Cys
 20 25 30
 Lys Glu Val Gly Ala Gln Leu Val Val Ile Lys Ser Ala Glu Glu Gln
 35 40 45
 Asn Phe Leu Gln Leu Gln Ser Ser Arg Ser Asn Arg Phe Thr Trp Met
 50 55 60
 Gly Leu Ser Asp Leu Asn Gln Glu Gly Thr Trp Gln Trp Val Asp Gly
 65 70 75 80
 Ser Pro Leu Leu Pro Ser Phe Lys Gln Tyr Trp Asn Arg Gly Glu Pro
 85 90 95

SUBSTITUTE SHEET

- 23 -

Asn Asn Val Gly Glu Glu Asp Cys Ala Glu Phe Ser Gly Asn Gly Trp
 100 105 110

Asn Asp Asp Lys Cys Asn Leu Ala Lys Phe Trp Ile Cys Lys Lys
 115 120 125

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 126 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Cys Gly Ala Gln Ser Arg Gln Trp Glu Tyr Phe Glu Gly Arg Cys Tyr
 1 5 10 15
 Tyr Phe Ser Leu Ser Arg Met Ser Trp His Lys Ala Lys Ala Glu Cys
 20 25 30
 Glu Glu Met His Ser His Leu Ile Ile Ile Asp Ser Tyr Ala Lys Gln
 35 40 45
 Asn Phe Val Met Phe Arg Thr Arg Asn Glu Arg Phe Trp Ile Gly Leu
 50 55 60
 Thr Asp Glu Asn Gln Glu Gly Glu Trp Gln Trp Val Asp Gly Thr Asp
 65 70 75 80
 Thr Arg Ser Ser Phe Thr Phe Trp Lys Glu Gly Glu Pro Asn Asn Arg
 85 90 95
 Gly Phe Asn Glu Asp Cys Ala His Val Trp Thr Ser Gly Gln Trp Asn
 100 105 110
 Asp Val Tyr Cys Thr Tyr Glu Cys Tyr Tyr Val Cys Glu Lys
 115 120 125

(2) INFORMATION FOR SEQ ID NO: 5:

SUBSTITUTE SHEET

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 125 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

```
Cys Asn Thr Cys Pro Glu Lys Trp Ile Asn Phe Gln Arg Lys Cys Tyr
1          5          10          15
Tyr Phe Gly Lys Gly Thr Lys Gln Trp Val His Ala Arg Tyr Ala Cys
20          25          30
Asp Asp Met Glu Gly Gln Leu Val Ser Ile His Ser Pro Glu Glu Gln
35          40          45
Asp Phe Leu Thr Lys His Ala Ser His Thr Gly Ser Trp Ile Gly Leu
50          55          60
Arg Asn Leu Asp Leu Lys Gly Glu Phe Ile Trp Val Asp Gly Ser His
65          70          75          80
Val Asp Tyr Ser Asn Trp Ala Pro Gly Glu Pro Thr Ser Arg Ser Gln
85          90          95
Gly Glu Asp Cys Val Met Met Arg Gly Ser Gly Arg Trp Asn Asp Ala
100          105          110
Phe Cys Asp Arg Lys Leu Gly Ala Trp Val Cys Asp Arg
115          120          125
```

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 129 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

SUBSTITUTE SHEET

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

```

Arg Thr Cys Cys Pro Val Asn Trp Val Glu His Glu Arg Ser Cys Tyr
1           5           10           15
Trp Phe Ser Arg Ser Gly Lys Ala Trp Ala Asp Ala Asp Asn Tyr Cys
20           25           30
Arg Leu Glu Asp Ala His Leu Val Val Val Thr Ser Trp Glu Glu Gln
35           40           45
Lys Phe Val Gln His His Ile Gly Pro Val Asn Thr Trp Met Gly Leu
50           55           60
His Asp Gln Asn Gly Pro Trp Lys Trp Val Asp Gly Thr Asp Tyr Glu
65           70           75           80
Thr Gly Phe Lys Asn Trp Arg Pro Glu Gln Pro Asp Asp Trp Tyr Gly
85           90           95
His Gly Leu Gly Gly Gly Glu Asp Cys Ala His Phe Thr Asp Asp Gly
100          105          110
Arg Trp Asn Asp Asp Val Cys Gln Arg Pro Tyr Arg Trp Val Cys Glu
115          120          125
Thr

```

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 129 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

SUBSTITUTE SHEET

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Arg Thr Cys Cys Pro Val Asn Trp Val Glu His Gln Gly Ser Cys Tyr
1 5 10 15
Trp Phe Ser His Ser Gly Lys Ala Trp Ala Glu Ala Glu Lys Tyr Cys
20 25 30
Gln Leu Glu Asn Ala His Leu Val Val Ile Asn Ser Trp Glu Glu Gln
35 40 45
Lys Phe Ile Val Gln His Thr Asn Pro Phe Asn Thr Trp Ile Gly Leu
50 55 60
Thr Asp Ser Asp Gly Ser Trp Lys Trp Val Asp Gly Thr Asp Tyr Arg
65 70 75 80
His Asn Tyr Lys Asn Trp Ala Val Thr Gln Pro Asp Asn Trp His Gly
85 90 95
His Glu Leu Gly Gly Ser Glu Asp Cys Val Glu Val Gln Pro Asp Gly
100 105 110
Arg Trp Asn Asp Asp Phe Cys Leu Gln Val Tyr Arg Trp Val Cys Glu
115 120 125
Lys

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 130 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Leu Gln Leu Ile Met Gln Asp Trp Lys Tyr Phe Asn Gly Lys Phe Tyr
1 5 10 15

SUBSTITUTE SHEET

Tyr Phe Ser Arg Asp Lys Lys Ser Trp His Glu Ala Glu Asn Phe Cys
 20 25 30
 Val Ser Gln Gly Ala His Leu Ala Ser Val Thr Ser Gln Glu Glu Gln
 35 40 45
 Ala Phe Leu Val Gln Ile Thr Asn Ala Val Asp His Trp Ile Gly Leu
 50 55 60
 Thr Asp Gln Gly Thr Glu Gly Asn Trp Arg Trp Val Asp Gly Thr Pro
 65 70 75 80
 Phe Asp Tyr Val Gln Ser Arg Arg Phe Trp Arg Lys Gly Gln Pro Asp
 85 90 95
 Asn Trp Arg His Gly Asn Gly Glu Arg Glu Asp Cys Val His Leu Gln
 100 105 110
 Arg Met Trp Asn Asp Met Ala Cys Gly Thr Ala Tyr Asn Trp Val Cys
 115 120 125
 Lys Lys
 130

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 130 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

Pro Thr His Cys Pro Ser Gln Trp Trp Pro Tyr Ala Gly His Cys Tyr
 1 5 10 15
 Lys Ile His Arg Asp Glu Lys Lys Ile Gln Arg Asp Ala Leu Thr Thr
 20 25 30
 Cys Arg Lys Glu Gly Gly Asp Leu Thr Ser Ile His Thr Ile Glu Glu
 35 40 45

SUBSTITUTE SHEET

WO 93/01820

- 28 -

Leu Asp Phe Ile Ile Ser Gln Leu Gly Leu Glu Pro Asn Asp Glu Leu
 50 55 60
 Trp Ile Gly Leu Asn Asp Ile Lys Ile Gln Met Tyr Phe Glu Trp Ser
 65 70 75 80
 Asp Gly Thr Pro Val Thr Phe Thr Lys Trp Leu Arg Gly Glu Pro Ser
 85 90 95
 His Glu Asn Asn Arg Gln Glu Asp Cys Val Val Met Lys Gly Lys Asp
 100 105 110
 Gly Tyr Trp Ala Asp Arg Gly Cys Glu Trp Pro Leu Gly Tyr Ile Cys
 115 120 125
 Lys Met
 130

SUBSTITUTE SHEET

We claim:

1. A method of inhibiting HIV infection of mammalian cells comprising contacting the cells with an effective amount of a compound selected from the group consisting of a mannose carbohydrate, a fucose carbohydrate, a lectin and a drug, for a time period sufficient to significantly inhibit the binding of HIV to a non-CD4 cell surface protein.
2. The method of Claim 1, wherein the non-CD4 cell surface protein is a gp120 receptor having a specific binding affinity for gp120 of about $K_d = 1.3 \text{ nM}$ to about $K_d = 2.0 \text{ nM}$.
3. The method of Claim 2, wherein the gp120 receptor is present on placental cells.
4. The method of Claim 2, wherein the gp120 receptor is present on muscle cells.
5. The method of Claim 2, wherein the gp120 receptor is present on neural cells.
6. The method of Claim 5, wherein the neural cells are brain cells.
7. The method of Claim 5, wherein the neural cells are dendritic cells.
8. The method of Claim 2, wherein the gp120 receptor is present on mucosal cells.
10. The method of Claim 1, wherein the compound is mannose.
10. The method of Claim 1, wherein the compound is fucose.
11. The method of Claim 1, wherein the compound is a mannose-containing carbohydrate.
12. The method of Claim 11, where the carbohydrate is mannan.
13. The method of Claim 1, wherein the compound is a pradimicin A antibiotic.
14. A substantially purified non-CD4 gp120 receptor protein comprising a protein substantially corresponding to a non-CD4 mammalian cell surface protein that has a

SUBSTITUTE SHEET

specific binding affinity for gp120, said protein containing about 400 amino acid residues, having a molecular weight of about 45,000 daltons and having a binding affinity for gp120 characterized by a K_d of about 1.3 nM to about 2 nM.

15. The gp120 receptor protein of Claim 14, wherein the binding of the gp120 receptor protein to gp120 is inhibited by a compound selected from the group consisting of a mannose carbohydrate, a fucose carbohydrate, a lectin and a drug.
16. The gp120 receptor of Claim 15, wherein the compound is mannose.
17. The gp120 receptor protein of Claim 15, wherein the compound is a pradimicin A antibiotic.
18. The gp120 receptor protein of Claim 14, wherein the protein is produced by recombinant means.
19. The gp120 receptor protein of Claim 18, wherein said recombinant means comprises the cloning of a cDNA isolated from a library of recombinant placental genes.
20. A DNA molecule encoding the gp120 receptor protein of Claim 14, wherein the DNA is a complementary DNA that transcribes an mRNA found in cells selected from the group consisting of placental cells, brain cells, muscle cells and colon cells.
21. A method of detecting the presence of HIV in a sample comprising:
 - (a) admixing in an aqueous medium a sample to be assayed with a non-CD4 gp120 receptor protein having a specific binding affinity for gp120 characterized by a K_d of about 1.3 nM to about 2.0 nM in an amount sufficient to carry out at least one assay;
 - (b) maintaining the admixture for a time period sufficient for the gp120 receptor protein to bind to any HIV present in the sample and form a reaction product; and
 - (c) determining the presence of the HIV containing reaction product.

SUBSTITUTE SHEET

22. The method of Claim 21, wherein the gp120 receptor protein contains about 400 amino acid residues and has a molecular weight of about 45,000 daltons.
23. The method of Claim 21, wherein the gp120 receptor protein is affixed to a solid matrix to form a solid support.
24. The method of Claim 21, wherein the presence of the reaction product is determined by contacting the sample with a reagent capable of detecting the bound gp120 receptor protein.
25. The method of Claim 24, wherein the reagent is a labelled antibody directed against the gp120 receptor protein.
26. A diagnostic system in kit form, for assaying for the presence of HIV in a fluid sample, comprising a package containing a non-CD4 receptor protein having a specific affinity for gp120 characterized by a Kd of about 1.3 nM to about 2.0 nM, and instructions for use.
27. The diagnostic system of Claim 26, wherein the non-CD4 gp120 receptor protein is affixed to a solid matrix to form a solid support.

SUBSTITUTE SHEET




Figure 1A

SUBSTITUTE SHEET

2/12




Figure 1B

SUBSTITUTE SHEET




Figure 1C

4/12




Figure 2A




Figure 2B

SUBSTITUTE SHEET

6/12




Figure 2C

SUBSTITUTE SHEET

7/12




Figure 2D

SUBSTITUTE SHEET

8/12




Figure 2E

SUBSTITUTE SHEET

1 CTAAAGCAGGAGTTCTGGACACTGGGGGAGAGTGGGGTGAC

42 ATGAGTGA CTCCAAGGAACCAAGACTGCAGCAGCTGGGCCTCCTGGAGGAGGAACAGCTG
1 M S D S K E P R L Q Q L G L L E E E Q L

102 AGAGGCCTTGGATTCCGACAGACTCGAGGATACAAGAGCTTAGCAGGGTGTCTTGGCCAT
21 R G L G F R Q T R G Y K S L A G C L G H

162 GGTCCCCTGGTGCTGCAACTCCTCTCCTTCACGCTCTTGGCTGGGCTCCTTGTCCAAGTG
41 G P L V L O L L S F T L L A G L L V Q V

222 TCCAAGGTCCCCAGCTCCATAAGTCAGGAACAATCCAGGCAAGACGCGATCTACCAGAAC
61 S K V P S S I S Q E Q S R Q D A I Y Q N

282 CTGACCCAGCTTAAAGCTGCAGTGGGTGAGCTCTCAGAGAAATCCAAGCTGCAGGAGATC
81 L T Q L K A A V G E L S E K S K L Q E I

342 TACCAGGAGCTGACCCAGCTGAAGGCTGCAGTGGGTGAGCTTCCAGAGAAATCTAAGCTG
101 Y Q E L T Q L K A A V G E L P E K S K L

402 CAGGAGATCTACCAGGAGCTGACCCGGCTGAAGGCTGCAGTGGGTGAGCTTCCAGAGAAA
121 Q E I Y Q E L T R L K A A V G E L P E K

462 TCTAAGCTGCAGGAGATCTACCAGGAGCTGACCTGGCTGAAGGCTGCAGTGGGTGAGCTT
141 S K L Q E I Y Q E L T W L K A A V G E L

522 CCAGAGAAATCTAAGATGCAGGAGATCTACCAGGAGCTGACTCGGCTGAAGGCTGCAGTG
161 P E K S K M Q E I Y Q E L T R L K A A V

582 GGTGAGCTTCCAGAGAAATCTAAGCAGCAGGAGATCTACCAGGAGCTGACCCGGCTGAAG
181 G E L P E K S K Q Q E I Y Q E L T R L K

642 GCTGCAGTGGGTGAGCTTCCAGAGAAATCTAAGCAGCAGGAGATCTACCAGGAGCTGACC
201 A A V G E L P E K S K Q Q E I Y Q E L T

702 CGGCTGAAGGCTGCAGTGGGTGAGCTTCCAGAGAAATCTAAGCAGCAGGAGATCTACCAG
221 R L K A A V G E L P E K S K Q Q E I Y Q

762 GAGCTGACCCAGCTGAAGGCTGCAGTGGAACGCCTGTGCCACCCCTGTCCCTGGGAATGG
241 E L T Q L K A A V E R L C H P C P W E W
L

822 ACATTCTTCCAAGGAACTGTTACTTCATGTCTAACTCCCAGCGGAACTGGCAGGACTCC
261 T F F Q G N C Y F M S N S Q R N W H D S

Figure 3A

SUBSTITUTE SHEET

10/12

882 ATCACCGCCTGCAAAGAAGTGGGGGCCAGCTCGTCGTAATCAAAGTGCTGAGGAGCAG
281 I T A C K E V G A Q L V V I K S A E E Q

942 AACTTCCTACAGCTGCAGTCTTCCAGAAGTAACCGCTTCACCTGGATGGGACTTTCAGAT
301 N F L Q L Q S S R S N R F T W M G L S D

1002 CTAAATCAGGAAGGCACGTGGCAATGGGTGGACGGCTCACCTCTGTTGCCCAGCTTCAAG
321 L N Q E G T W Q W V D G S P L L P S F K

1062 CAGTATTGGAACAGAGGAGAGCCCAACAACGTTGGGGAGGAAGACTGCGCGGAATTTAGT
341 Q Y W N R G E P N N V G E E D C A E F S

1122 GGCAATGGCTGGAACGACGACAAATGTAATCTTGCCAAATTCTGGATCTGCAAAAAGTCC
361 G N G W N D D K C N L A K F W I C K K S

1182 GCAGCCTCCTGCTCCAGGGATGAAGAACAGTTTCTTTCTCCAGCCCCTGCCACCCCAAAC
381 A A S C S R D E E Q F L S P A P A T P N

1242 CCCCTCCTGCGTAGCAGAACTTCACCCCTTTTAAGCTACAGTTCCTTCTCTCCATCCT
401 P P P A ***

1302 TCGACCTTTAG

Figure 3A (cont.)

SUBSTITUTE SHEET

11/12




Figure 3B

12/12

```

9p120(253)CHPCHEWETFFQNCYFMSNS-QRNWHTSITACKEVGAQLVVIKSAEEQNFLQLQ-SSRSNRFWTMG
CHL(78)CGAQSRCQWEYFEBRCYFYSLS-RMSWTKAKACEEMHSHITIDSYAKQNFVMFR--TRNERF--WTMG
Iger(160)CNTCHEKMINFQRKCYFYGKG-TKQWVHARYACDDNEGQLVSIHSPFEEQFLTKH-ASHTG--SWMG
H1(148)RTQCHVNVVEHSCYMFYSRS-GKAWADADNYCRLEDAHLVVVTSWEEQKFLVQH-IGPVN--TWMG
H2(174)RTQCHVNVVEHQSCYMFYSRS-GKAWAEAEKYQLENAHLVVVINSWEEQKFLVQH-TNPFN--TWMG
Kupff(409)LQLIMQDMKYENKCYFYSRD-KKSWHEAENFCVSQGAHLASVTSQEECAFIVQI-TNAVVDH--WTMG
Mannr(341)PTHCFSQWMPYAGHCYKTHRDEKKIQRAITTCRKEGGDLTSTHTIEELDFIISQLGLEPNDDELWTMG

ISDLNQEGLMQWVDGSHL-LPSFKQYMNREGEPNNV-----GEEDCAEFSCN-G-WNDDKCNLAKF-WICKK ALIGN
ITDENQEGEWQWVDGTDI-TSSFT-FMKEGEPNNR-----GFNEDCAHVWTS-GQWNDVYCTYECY-YVCEK 17.5
LRNLDLKGEFLMVDGSHV---DYSN-WAFGEFTSRS-----QGEDQVMTSGS-GRWDAFCORKLGAWVCDR 15.6
LHD--QNGPMMWVDGTDY-ETGFKN-MRPEQDDWYGHGLGGGEDCAHEITDD-GRWDDVC-QRPYRWVDET 13.1
LTD--SDGSMKWVDGTDY-RHNYKN-MAVTQFDNWHGHELGESEDCVIEVQPD-GRWDDFC-LQVYRWVCEK 12.9
LTDQGTENMRWVDGTFFDYVQSRFRMRKGGFDNWRHGN-GEREDQVHLQRM---WNDMACGTB-YNWWCKK 13.2
LNDIKIQMYFEWSDGTIPV---TFTK-MIRGEHSHENN-----RQEDQVMMKCKGVWADRGCCEWPLG-YICKM 11.6

```

Figure 3C

SUBSTITUTE SHEET

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 15/12, C07K 13/00 G01N 33/50, 33/68, C12Q 1/70 A61K 31/70, 31/715	A3	(11) International Publication Number: WO 93/01820 (43) International Publication Date: 4 February 1993 (04.02.93)
---	----	---

(21) International Application Number: PCT/US92/05985

(22) International Filing Date: 16 July 1992 (16.07.92)

(30) Priority data:
731,214 16 July 1991 (16.07.91) US(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/
US]; 345 Park Avenue, New York, NY 10154 (US).(72) Inventor: CURTIS, Benson, M. ; 1520 N.W. Woodbine
Way, Seattle, WA 98177 (US).(74) Agents: POOR, Brian, W.; Bristol-Myers Squibb Com-
pany, 3005 First Avenue, Seattle, WA 98121 (US) et al.(81) Designated States: AU, CA, FI, JP, KR, NO, European
patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU,
MC, NL, SE).**Published***With international search report.
Before the expiration of the time limit for amending the
claims and to be republished in the event of the receipt of
amendments.*(88) Date of publication of the international search report:
27 May 1993 (27.05.93)

(54) Title: INHIBITION OF NON-CD4 MEDIATED HIV INFECTION

(57) Abstract

A specific nonCD4-gp120 receptor has been isolated which has specific binding affinity for the gp120 surface protein of human immunodeficiency virus (HIV). Methods of treating HIV infection of CD4 negative cells, such as colon and brain, are disclosed together with methods of detecting HIV and diagnostic kits.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 92/05985

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 C12N15/12; C12Q1/70;	C07K13/00; A61K31/70;	G01N33/50; A61K31/715
G01N33/68		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	C12N ; C07K ; A61K	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
P,X	JOURNAL OF MEDICAL VIROLOGY vol. 35, no. 3, November 1991, pages 187 - 191 MORRISON, N.K. ET AL.; 'Growth of human immunodeficiency virus 1 in cultured cells in the absence of the CD4 antigen.' see the whole document	1-11
X	AIDS vol. 3, no. 12, 1989, pages 793 - 798 LARKIN, M. ET AL.; 'Oligosaccharide-mediated interactions of the envelope glycoprotein gp120 of HIV-1 that are independent of CD4 recognition' cited in the application see the whole document	1-11
<p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search 22 FEBRUARY 1993		Date of Mailing of this International Search Report 23. 04. 93
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer NAUCHE S.A.

Form PCT/ISA/210 (second sheet) (January 1983)

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		Relevant to Claim No.
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	
A	<p>BULL. INST. PASTEUR vol. 89, no. 2, June 1991, IZRACHI, Y. ET AL.; 'Efficient binding , fusion and entry of HIV1 into CD4 negative neural cells : a mechanism for neuropathogenesis in Aids.' see the whole document</p> <p>---</p>	1-11
A	<p>NATURE. vol. 337, 1989, LONDON GB pages 368 - 370 CLAPHAM, P.R. ET AL.; 'Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells.' cited in the application see the whole document</p> <p>---</p>	1-11
A	<p>THE JOURNAL OF EXPERIMENTAL MEDECINE vol. 169, January 1989, THE ROCKEFELLER UNIV. PRESS pages 185 - 196 EZEKOWITZ, R.A.B. ET AL.; 'A human serum mannose binding protein inhibits in vitro infection by the human immunodeficiency virus.' see the whole document</p> <p>---</p>	1-12, 14-27
T	<p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 89, September 1992, WASHINGTON US pages 8356 - 8360 Curtis, Benson M.; Scharnowske, S.; Watson, A.J.; 'Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp120.'</p> <p>-----</p>	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 92/05985

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-11
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 1-11 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please see our invitation PCT/ISA/206 of 30.11.92

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
1-8 (partially), 9-12
14-27
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

This Page Blank (uspto)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

This Page Blank (uspto)